Niaspan Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials

Merck Provides Update on Next Steps for Tredaptive (extended-release niacin/laropiprant)
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Jan 11, 2013 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the company is taking steps to suspend the availability of TREDAPTIVE™... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 11, 2013 Category: Pharmaceuticals Source Type: clinical trials

A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
Conditions:   Hypercholesterolemia, Familial;   Heterozygous Familial HypercholesterolemiaInterventions:   Drug: MK-0524A;   Drug: MK-0524ASponsor:   Merck Sharp & Dohme Corp.Terminated - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2012 Category: Research Source Type: clinical trials